Drug news
Farletuzumab (Morphotek) now in Phase III trial for Ovarian Cancer
Morphotek/Eisai has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase III randomized trial of Farletuzumab in first-relapsed patients with platinum-sensitive ovarian cancer. Farletuzumab is a humanized monoclonal antibody that targets folate receptor alpha (FRA), which is expressed on the majority of non-mucinous epithelial ovarian cancers as well as a subset of other carcinomas.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.